Dermal Safety Study of JTE-052

Phase I Clinical Study of JTE-052 new drug product - Dermal Safety Study -

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230570

Enrollment

Registered

2024-01-16

Start date

2024-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Single application of JTE-052 0.5%

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Healthy Japanese males aged from 20 to 45 years 2.Those with a body mass index (BMI) of 18.5 to less than 25.0

Exclusion criteria

Exclusion criteria: 1.Those who have skin conditions that may affect the evaluation in the study, e.g., eczema, dermatitis, pigmentation abnormality, inflammation caused by sunburn, injury, scar, and excessive hair growth, at the prospective application site 2.Those who have a history of contact dermatitis caused by dermatological drugs, adhesive plaster, tape, etc. mechanical urticaria, dermal hypersensitivity, or atopic dermatitis 3.Those to whom JTE-052 has been administered in the past 4.Those for whom the investigator judged it problematic to participate in the study

Design outcomes

Primary

Measure	Time frame
Potential for skin irritation	—

Contacts

Public Contactinformation clinical trials

Shionogi & Co.,Ltd.

clinicaltrials-info@shionogi.co.jp+81-3-6635-3505

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026